Asset Details
Do you wish to reserve the book?
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Do you wish to request the book?
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
2019
Overview
In a randomized trial, patients who received evobrutinib, an inhibitor of Bruton’s tyrosine kinase, at 75 mg daily had significantly fewer enhancing lesions on MRI during weeks 12 through 24 than those who received placebo. However, there was no significant between-group difference for either a lower or a higher dose of evobrutinib, or in the annualized relapse rate or disability progression at any dose.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors
/ Antigens
/ Dimethyl Fumarate - therapeutic use
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Male
/ Multiple Sclerosis - drug therapy
/ Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging
/ Multiple Sclerosis, Relapsing-Remitting - drug therapy
/ Multiple Sclerosis, Relapsing-Remitting - pathology
/ NMR
/ Piperidines - administration & dosage
/ Piperidines - adverse effects
/ Piperidines - therapeutic use
/ Protein Kinase Inhibitors - administration & dosage
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - therapeutic use
/ Pyrimidines - administration & dosage
/ Pyrimidines - adverse effects
